AOD-9604 UK: Complete Research Guide (2026)

What is AOD-9604?

AOD-9604 is a modified fragment of human growth hormone (HGH), specifically designed to retain the fat-burning properties of the parent hormone whilst removing growth-promoting effects. The peptide comprises amino acids 176-191 of the C-terminal region of human growth hormone, with a tyrosine substitution at position 2.

Unlike full HGH, which can promote insulin resistance and hyperglycaemia at higher doses, AOD-9604 targets lipolytic pathways specifically. This makes it a popular subject in metabolic research, particularly for understanding fat loss mechanisms without the systemic growth effects of endogenous HGH.

Mechanism of Action

AOD-9604 operates through a distinct mechanism compared to full growth hormone. Research suggests the peptide binds to specific receptors on adipocytes (fat cells), triggering lipolytic activity—the breakdown of triglycerides into free fatty acids and glycerol.

Lipolytic Activity

The primary mechanism involves activation of hormone-sensitive lipase (HSL), an enzyme critical for fat mobilisation. Studies indicate AOD-9604 increases lipolysis in a dose-dependent manner, with effects observed across both visceral and subcutaneous fat deposits.

Unlike catecholamines or other sympathomimetic agents, AOD-9604 does not significantly elevate heart rate or blood pressure in research models, suggesting a selective pathway of action.

Fat Metabolism and Metabolic Rate

Beyond lipolysis, research indicates AOD-9604 may influence metabolic rate through thermogenic pathways. Some studies suggest the peptide enhances oxidative metabolism, though the exact mechanism remains under investigation.

Importantly, AOD-9604 does not appear to suppress appetite centres in the hypothalamus, distinguishing it from GLP-1 agonists and other weight management compounds.

Fat Loss and Metabolic Research Findings

Clinical and preclinical research on AOD-9604 has demonstrated consistent effects on adipose tissue metabolism. Early studies showed dose-dependent increases in lipolysis in isolated adipocytes, with effects becoming apparent at nanomolar concentrations.

In animal models, AOD-9604 administration resulted in significant reductions in body weight and fat mass over 4-12 week periods, whilst preserving lean muscle mass. This selective fat loss without generalised weight reduction is a hallmark finding across multiple studies.

Human observational data, though limited in rigorous clinical trials, suggests similar patterns. Researchers have noted improvements in body composition metrics and metabolic markers in research participants receiving AOD-9604 protocols.

Research on Visceral Fat

Visceral adiposity (deep abdominal fat) is metabolically distinct from subcutaneous fat and carries greater metabolic risk. Evidence suggests AOD-9604 may preferentially mobilise visceral fat stores, though subcutaneous deposits are also affected.

Cartilage and Joint Repair Research

Beyond fat metabolism, AOD-9604 has garnered research interest for musculoskeletal applications. The parent HGH molecule is known to stimulate chondrocyte (cartilage cell) proliferation and extracellular matrix synthesis.

Studies investigating AOD-9604’s effects on cartilage indicate the peptide may promote anabolic activity in chondrocytes, potentially supporting joint integrity and cartilage regeneration pathways. This mechanism appears independent of its lipolytic effects, suggesting distinct signalling pathways.

Research on AOD-9604 in osteoarthritis models has shown promise, though human clinical data remains limited. The peptide’s potential to support cartilage homeostasis makes it a subject of ongoing investigation in regenerative medicine research.

AOD-9604 vs HGH Fragment 176-191: Are They the Same?

A common question in peptide research circles concerns the distinction between AOD-9604 and HGH Fragment 176-191 (also called GH Fragment 176-191).

Technically, they are nearly identical, but with one critical modification: AOD-9604 contains a tyrosine substitution at the N-terminal position (replacing the native phenylalanine). This single amino acid change was engineered to improve the peptide’s stability and bioavailability in research applications.

HGH Fragment 176-191 represents the unmodified sequence; AOD-9604 is the pharmaceutical-grade variant optimised for research use. In practice, both peptides target similar lipolytic pathways, though AOD-9604’s enhanced stability may allow for more consistent dosing protocols.

AOD-9604 vs Semaglutide/GLP-1 Agonists: Mechanisms in Fat Loss Research

The rise of GLP-1 receptor agonists (including semaglutide) has prompted researchers to compare their fat loss mechanisms against AOD-9604. These are fundamentally different compounds with distinct pathways.

GLP-1 Agonists: Appetite and Satiety

Semaglutide and similar GLP-1 compounds work primarily through central nervous system pathways, promoting satiety and reducing appetite. Weight loss occurs largely through decreased caloric intake.

AOD-9604: Direct Lipolytic Action

AOD-9604, by contrast, works via direct peripheral lipolysis—mobilising stored fat independently of appetite regulation. Fat loss occurs through increased fat cell breakdown and mobilisation, not reduced food intake.

Comparative Research Context

From a research perspective, AOD-9604 is valuable for studying metabolic pathways and fat cell biology in isolation from appetite centres. GLP-1 agonists are better for investigating satiety mechanisms and integrated metabolic control.

Some research has explored combining these compounds, though clinical safety and efficacy data for such protocols remains limited. Each offers distinct insights into weight management physiology.

Safety Profile and Research Observations

AOD-9604 has demonstrated a favourable safety profile in research settings. As a peptide fragment without growth-promoting activity, it avoids many of the metabolic complications associated with full HGH therapy, such as insulin resistance or carpal tunnel syndrome.

Observed Adverse Events

Research protocols typically report mild injection site reactions (erythema, oedema) as the most common observation. Systemic adverse effects have been minimal in most studies.

Unlike growth hormone, AOD-9604 does not appear to elevate glucose levels or promote hyperglycaemia, making it suitable for research in metabolically compromised populations.

Cardiovascular Considerations

AOD-9604 does not significantly alter heart rate or blood pressure in research settings, unlike some sympathomimetic fat-loss compounds. Lipid profiles and inflammatory markers typically show favourable changes or remain stable.

Long-term Safety Data

Whilst short-term safety data (12-24 weeks) is robust, long-term safety data in humans remains limited. Most research has focused on 4-16 week protocols. This is an important consideration for any extended research applications.

Dosing Protocols Observed in Studies

AOD-9604 dosing in research has varied considerably depending on study design and objectives. Typical protocols observed include:

Daily subcutaneous injection: 0.3-1.0 mg per day, administered once daily in the morning or divided into two doses. Most studies utilising daily dosing employed 0.5-0.75 mg daily.

Intermittent protocols: Some research has employed three times weekly dosing at 1.0-2.0 mg per injection, based on the peptide’s half-life and receptor kinetics.

Dosing duration: Research protocols typically span 8-16 weeks, with some extended studies running up to 24 weeks. Re-evaluation intervals of 4-6 weeks are common in study designs.

Dose-response relationships have been documented, with effects generally plateauing at higher doses. Individual variation in response is notable, likely reflecting differences in adipocyte receptor density and metabolic phenotypes.

Storage and Reconstitution

Proper handling ensures research integrity and peptide stability. AOD-9604 is supplied as a lyophilised (freeze-dried) powder and must be reconstituted before use.

Storage of Lyophilised Powder

Unopened vials should be stored at 2-8°C (refrigerated) or at room temperature (15-25°C) if stored in a cool, dry location away from light. Stability typically extends 2-3 years under proper conditions. Check the Certificate of Analysis (CoA) provided by your supplier for specific stability data.

Reconstitution

The peptide is reconstituted using bacteriostatic water (sterile water containing 0.9% benzyl alcohol). Reconstitution protocols vary; most commonly 1-2 mL of bacteriostatic water is added to a 5 mg vial, creating a concentration of 2.5-5.0 mg/mL.

Reconstituted AOD-9604 should be stored at 2-8°C and is typically stable for 14-30 days, depending on reconstitution conditions and storage temperature. Always consult your supplier’s specific stability data.

Injection Technique

Research protocols typically employ subcutaneous injection using sterile insulin syringes. Common injection sites include the abdomen, thigh, or upper arm. Site rotation is standard practice to minimise local tissue irritation.

UK Legal Status

AOD-9604 is not a controlled substance under UK law. It is not licensed as a medicine for human use and therefore falls outside the remit of the Human Medicines Regulations 2012.

However, supply and use are regulated under the Medicines Act 1968. AOD-9604 may be legally supplied for research and laboratory use only—that is, for in vitro studies, animal research, and investigational research purposes.

It is not legal to supply AOD-9604 for human consumption or therapeutic use without appropriate licensing. Reputable UK suppliers explicitly market their products for research use only and include appropriate disclaimers.

Customers must acknowledge the research use only status and agree not to use the product for unapproved human applications. This legal framework protects both suppliers and researchers whilst allowing legitimate scientific investigation.

UK Sourcing Guidance

When sourcing AOD-9604 for research purposes in the UK, several factors ensure quality and legality:

Supplier Credentials

Reputable UK suppliers should provide:

• Certificate of Analysis (CoA) from an independent third-party laboratory, confirming peptide identity and purity
• Explicit “research use only” disclaimers
• Clear company registration and physical address
• Transparent about manufacturing standards (GMP certification preferred)

Quality Standards

Look for suppliers offering peptides with purity above 98%. CoAs should include HPLC (High-Performance Liquid Chromatography) analysis and mass spectrometry confirmation of peptide identity.

Avoid suppliers offering vague quality claims or reluctant to provide analysis documentation. The peptide you receive should match its specification exactly.

Pricing Context

AOD-9604 research-grade peptides in the UK typically cost £80-150 per 5 mg vial, depending on purity and supplier. Prices below this range may indicate lower quality or diluted product; significantly higher prices suggest markup rather than quality premium.

Frequently Asked Questions

Is AOD-9604 the same as HGH?

No. AOD-9604 is a small peptide fragment (15 amino acids) derived from HGH’s C-terminal region. It lacks the growth-promoting effects of full HGH but retains lipolytic properties.

Does AOD-9604 cause insulin resistance like HGH?

Research suggests AOD-9604 does not significantly impair glucose metabolism or promote insulin resistance, unlike full growth hormone at higher doses. Metabolic markers typically remain stable or improve.

How quickly does AOD-9604 work?

Lipolytic effects become apparent within 1-2 weeks of starting protocols in most research. Peak effects are typically observed after 4-8 weeks of consistent use. Individual responses vary considerably.

Can AOD-9604 be combined with other peptides?

Research on combinations is limited. Theoretical interactions exist with other metabolic peptides (BPC-157, TB-500, etc.), but systematic safety data for combinations is lacking. Any combination should be approached cautiously with appropriate monitoring.

What is the half-life of AOD-9604?

The peptide has an approximate half-life of 5-7 minutes in circulation, meaning it is rapidly cleared. This short half-life drives dosing frequency and explains why frequent injections are employed in research protocols.

Does AOD-9604 require a prescription in the UK?

For research use, no prescription is required. However, supply is restricted to research and laboratory purposes. Marketing or supplying for human consumption would require appropriate regulatory approval (investigational new drug status or medicinal product licensing).

What storage temperature is best?

Reconstituted AOD-9604 is best stored at 2-8°C (standard refrigerator temperature). Lyophilised powder can be stored at room temperature or refrigerated, depending on supplier recommendations. Check your CoA for specific guidance.

Are there any interactions with common medications?

AOD-9604 does not significantly interact with standard medications in research settings. However, any combined use should be approached cautiously. Research on specific drug interactions remains limited.

What is the typical research duration?

Most published research protocols run 8-16 weeks. Some extended studies have gone 24 weeks. Optimal duration for your research purposes should be determined by your specific research objectives and monitoring protocols.

Research Disclaimer

AOD-9604 is supplied for research and laboratory use only. This product is not approved for human consumption or medical use. All information provided is for educational and research purposes only and should not be construed as medical advice.

Individuals considering any research involving AOD-9604 should consult appropriate medical professionals and adhere to all applicable regulations, ethics guidelines, and institutional review board requirements.

Peptide research carries inherent risks. Users are responsible for their own research methodology, adherence to regulatory requirements, and appropriate risk assessment.